Metabolism Disorder TRIZ Cases

Administering a beta-3 adrenergic receptor agonist stimulates angiogenesis and increases blood flow, reducing wound area and volume in diabetic foot ulcers.

Coenzyme Q10 and melatonin protect mitochondrial DNA from oxidative damage, maintaining cell viability for diabetes treatments.

Sequential growth factor induction produces functional beta cells from stem cells, eliminating polyhormonal contaminants that limit current diabetes therapies.

PKC activators drive stem cells toward pancreatic endoderm lineage, boosting PDX1 and NKX6.1 co-expression for functional beta cell generation.

Variable dosing intervals resolve the contradiction between fixed schedules and patient lifestyle adaptability.

Oral sorafenib inhibits Th1 cell differentiation, reducing pancreatic inflammation and avoiding systemic immunosuppression.

YAB peptides improve leptin resistance by targeting MC4 receptors to suppress food intake.

A concentrated liquid diet uses specific medium-chain fatty acids to supply energy efficiently.

A microneedle patch system delivers insulin via glucose signal amplification.

Quinoline compounds modulate SERCA enzyme activity to restore calcium homeostasis, addressing endoplasmic reticulum stress in neurodegenerative disorders.

Anti-A-FABP antibodies neutralize pathogenic fatty acid-binding protein to remove obesity-associated disease risk while preserving metabolic function.

Administering a CNS-targeted peptide improves glucose tolerance and reduces body fat, addressing limited efficacy in current diabetes therapies.

A polymer with metal salts achieves conductivity without conjugated bonds.

Composite polypeptide formulations reduce blood sugar concentrations while minimizing organ toxicity via natural proteolytic degradation.

Acid hydrolysis of cheese powder yields probiotic nanowhiskers that reduce cadmium concentration and serum MDA levels to alleviate oxidative stress.

Optimized water-ethanol extraction isolates soyasaponin I to lower plasma cholesterol while preserving prebiotic activity.

A nutritional composition combining omega-3 fatty acids, vitamin D, and plant extracts to support maternal health during breastfeeding.

Lipid nanoparticles deliver modified mRNA encoding GALT, reducing toxic metabolites in galactosemia type 1.

Modified oxyntomodulin analog extends half-life to improve insulin sensitivity while reducing side effects from high dosing requirements.

Reversible Fmoc linkers attach polyethylene glycol to oxyntomodulin, extending serum half-life and reducing dosing frequency.

Antibodies disrupt trimolecular complex assembly to inhibit autoimmune responses, preserving insulin-producing islets without broad immunosuppression.

Phosphonodifluoromethyl phenylalanine compounds inhibit PTP-MEG2 to enhance insulin signaling.

Humanized monoclonal antibodies inhibit vascular endothelial lipase to treat arteriosclerosis while reducing immunogenicity.

Identifies exercise-trained adipose tissue secreted proteins that mediate cross-talk with skeletal muscle and liver to improve glucose control.

Cinnamaldehyde activates TRPA1 channels to boost energy expenditure without the gastrointestinal intolerance caused by capsaicin.

Combining tazarotene with bexarotene boosts sulfatase activity, reducing substrate accumulation that causes early mortality in multiple sulfatase deficiency.

Glycolipid administration activates invariant NKT cells to modulate adipose inflammation and reverse obesity-associated metabolic disorders.

Bile acid-conjugated ionic polymers stabilize therapeutic genes for oral delivery, resolving toxicity and efficiency trade-offs in diabetes treatment.

Amodiaquine activates PPAR-gamma and PPAR-alpha to treat metabolic diseases while preventing obesity side effects.

Targeted amino acid substitutions in the FGF21 C-terminal fragment increase potency at the FGF receptor to treat metabolic disorders.

Engineered microorganisms modify PKS islands to reduce colibactin genotoxicity while maintaining anti-inflammatory effects.

Replacing fish oil supply chains by cultivating Thraustochytrium in heterotrophic media with oleic acid antagonists to stabilize DHA and EPA availability.

MOTS3 peptide modulates mitochondrial function to regulate metabolic homeostasis and glucose utilization.

Nutritional composition combines specific free amino acids with omega-3 fatty acids and soy protein hydrolysate.

A neuro-mesenchyme signaling axis controls group 2 innate lymphoid cells via sympathetic neurons and mesenchymal stromal cells.

Antisense oligonucleotides bind ANGPTL2 transcripts to suppress protein expression, addressing inadequate cardiovascular treatment effectiveness and cost.

Mutant CALB enzyme D223V/A281S maintains high R-ee above 99% at 5-70°C, resolving the trade-off between selectivity and productivity.

Adenoviral vector delivers base editor to fetus, avoiding immune responses that limit postnatal editing efficiency.

RARβ agonists resolve cardiovascular risk by controlling triglycerides, cholesterol, and inflammation.

Enzymatic hydrolysis of soy protein reduces viscosity while maintaining stability, resolving the trade-off between caloric capacity and flow resistance.

H2O2 scavenging enzymes eliminate toxicity risks while rapid micelle dissociation enables glucose-responsive insulin delivery.

Segmented tablet layers separate metformin from HMG-CoA inhibitors to prevent chemical decomposition while controlling release rates.

Peptides targeting perilipin-1 epitopes eliminate adipocytes via ADCC, avoiding gastrointestinal complications from surgical obesity treatments.

Co-polyamino acid prevents amyloid fibrillation, maintaining clarity at neutral pH.

Classifies subjects by metabolic genotype to select tailored dietary and exercise regimens, improving weight loss outcomes over traditional programs.